193 related articles for article (PubMed ID: 30593182)
1. Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
Liang CY; Chen DY; Mao CT; Hsieh IC; Hung MJ; Wang CH; Wen MS; Cherng WJ; Chen TH
Medicine (Baltimore); 2018 Dec; 97(52):e13844. PubMed ID: 30593182
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
Wang SH; Chen DY; Lin YS; Mao CT; Tsai ML; Hsieh MJ; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
PLoS One; 2015; 10(6):e0131122. PubMed ID: 26115092
[TBL] [Abstract][Full Text] [Related]
4. Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study.
Yang TY; Liaw YP; Huang JY; Chang HR; Chang KW; Ueng KC
Acta Diabetol; 2016 Jun; 53(3):461-8. PubMed ID: 26687195
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Su FC; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Cherng WJ; Chen TH
Medicine (Baltimore); 2015 Jul; 94(28):e1128. PubMed ID: 26181549
[TBL] [Abstract][Full Text] [Related]
6. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
7. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Engel SS; Suryawanshi S; Stevens SR; Josse RG; Cornel JH; Jakuboniene N; Riefflin A; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Obes Metab; 2017 Nov; 19(11):1587-1593. PubMed ID: 28432745
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus.
Zeng DK; Xiao Q; Li FQ; Tang YZ; Jia CL; Tang XW
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262972
[TBL] [Abstract][Full Text] [Related]
9. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
10. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
11. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
[TBL] [Abstract][Full Text] [Related]
12. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
13. Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks.
Chen TH; Wang CC; Liu CH; Hsiao CC; Chen ST; Liu FH; Ho MY; Li YR
Endocr Pract; 2020 Aug; 26(8):818-829. PubMed ID: 33471673
[TBL] [Abstract][Full Text] [Related]
14. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD.
Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1728-1739. PubMed ID: 33239410
[TBL] [Abstract][Full Text] [Related]
15. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Chan SY; Ou SM; Chen YT; Shih CJ
Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: A population-based case-control study in Taiwan.
Liao KF; Lin CL; Lai SW; Chen WC
Eur J Intern Med; 2016 Jan; 27():76-9. PubMed ID: 26433909
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.
Tseng CH
Ann Med; 2015; 47(7):561-9. PubMed ID: 26426676
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study.
Chang CH; Lin JW; Chen ST; Lai MS; Chuang LM; Chang YC
Medicine (Baltimore); 2016 Feb; 95(7):e2603. PubMed ID: 26886601
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
